Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Surgery
Erschienen in: Journal of Gastrointestinal Surgery 2/2011

01.02.2011 | Review Article

Radiofrequency Ablation Versus Resection for Liver Tumours: An Evidence-Based Approach to Retrospective Comparative Studies

verfasst von: Gianpiero Gravante, John Overton, Roberto Sorge, Neil Bhardwaj, Matthew S. Metcalfe, David M. Lloyd, Ashley R. Dennison

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Recently randomized controlled trials have been advocated to compare radiofrequency ablation (RFA) and hepatic resection (HR) in resectable tumours and determine whether differences in observed survivals result from the heterogeneity in previous studies between RFA (treating unresectable lesions) and HR (treating lesions deemed resectable). We reviewed the literature that directly compares the treatments and employed an evidence-based approach to examine the data.

Materials and Methods

All studies comparing RFA and HR were included. Primary outcomes were the overall survival (OS) and disease-free survival (DFS) at 3 and 5 years. A subgroup analysis was conducted for solitary or small tumors (<4 cm for colorectal metastases (CRM) or <5 cm for hepatocellular carcinoma (HCC)).

Results

Most studies were retrospective. For CRM, HR was markedly superior to RFA in respect of 3- and 5-year OS as well as 5-year DFS including tumours smaller than 4 cm and solitary lesions. For HCC, HR was markedly superior to RFA for 3- and 5-year OS as well as 3-year DFS, and produced a better OS at 3 years for solitary lesions and DFS at 3 years for small tumours.

Conclusions

Multiple factors determine outcomes following treatment of liver tumours. Small or solitary lesions seem the most appropriate ones to study as this reduces the number of confounding variables, but even in these cases HR confers a better OS and DFS than RFA for both CRM and HCC. If our data are confirmed it will be important to examine other factors influencing the response.
Literatur
1.
van den Broek, M. A., Olde Damink, S. W., Dejong, C. H., Lang, H., Malago, M., Jalan, R., and Saner, F. H. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 28: 767–780, 2008CrossRefPubMed
2.
Gravante, G., Sconocchia, G., Ong, S. L., Dennison, A. R., and Lloyd, D. M. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int 29: 18–24, 2009.CrossRefPubMed
3.
Seifert, J. K., and Morris, D. L. World survey on the complications of hepatic and prostate cryotherapy. World Journal of Surgery 23: 109–113; discussion 113–104, 1999CrossRefPubMed
4.
Sarantou, T., Bilchik, A., and Ramming, K. P. Complications of hepatic cryosurgery. Seminars in Surgical Oncology 14: 156–162, 1998.CrossRefPubMed
5.
Mulier, S., Miao, Y., Mulier, P., Dupas, B., Pereira, P., de Baere, T., Lencioni, R., Leveillee, R., Marchal, G., Michel, L., and Ni, Y. Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. Eur Radiol 15: 798–808, 2005.CrossRefPubMed
6.
Mulier, S., Ni, Y., Frich, L., Burdio, F., Denys, A. L., De Wispelaere, J. F., Dupas, B., Habib, N., Hoey, M., Jansen, M. C., Lacrosse, M., Leveillee, R., Miao, Y., Mulier, P., Mutter, D., Ng, K. K., Santambrogio, R., Stippel, D., Tamaki, K., van Gulik, T. M., Marchal, G., and Michel, L. Experimental and clinical radiofrequency ablation: proposal for standardized description of coagulation size and geometry. Annals of Surgical Oncology 14: 1381–1396, 2007.CrossRefPubMed
7.
Goldberg, S. N., Grassi, C. J., Cardella, J. F., Charboneau, J. W., Dodd, G. D., 3rd, Dupuy, D. E., Gervais, D. A., Gillams, A. R., Kane, R. A., Lee, F. T., Jr., Livraghi, T., McGahan, J., Phillips, D. A., Rhim, H., Silverman, S. G., Solbiati, L., Vogl, T. J., Wood, B. J., Vedantham, S., and Sacks, D. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20: S377–390, 2009.CrossRefPubMed
8.
Wemyss-Holden, S. A., Dennison, A. R., Berry, D. P., and Maddern, G. J. Local ablation for unresectable liver tumors: is thermal best? Journal of Hepato-Biliary-Pancreatic Surgery 11: 97–106, 2004.CrossRefPubMed
9.
Sutherland, L. M., Williams, J. A., Padbury, R. T., Gotley, D. C., Stokes, B., and Maddern, G. J. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 141: 181–190, 2006.CrossRefPubMed
10.
Mulier, S., Ni, Y., Jamart, J., Ruers, T., Marchal, G., and Michel, L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Annals of Surgery 242: 158–171, 2005.CrossRefPubMed
11.
Mulier, S., Mulier, P., Ni, Y., Miao, Y., Dupas, B., Marchal, G., De Wever, I., and Michel, L. Complications of radiofrequency coagulation of liver tumours. The British Journal of Surgery 89: 1206–1222, 2002.CrossRefPubMed
12.
Mulier, S., Ni, Y., Jamart, J., Michel, L., Marchal, G., and Ruers, T. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Annals of Surgical Oncology 15: 144–157, 2008.CrossRefPubMed
13.
Liang, P., Dong, B., Yu, X., Yu, D., Wang, Y., Feng, L., and Xiao, Q. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 235: 299–307, 2005.CrossRefPubMed
14.
Gravante, G. Thermal ablation for unresectable liver tumours, time to move forward? World J Gastrointest Surg 2: 1–5, 2010.CrossRefPubMed
15.
Seifert, J. K., and Morris, D. L. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Annals of Surgery 228: 201–208, 1998.CrossRefPubMed
16.
Seifert, J. K., and Morris, D. L. Indicators of recurrence following cryotherapy for hepatic metastases from colorectal cancer. The British Journal of Surgery 86: 234–240, 1999.CrossRefPubMed
17.
Gravante, G., Ong, S. L., Metcalfe, M. S., Bhardwaj, N., Lloyd, D. M., and Dennison, A. R. (2010) The effects of radiofrequency ablation on the hepatic parenchyma: Histological bases for tumor recurrences. Surgical Oncology. doi:10.​1016/​j.​suronc.​2010.​01.​005 PubMed
18.
Hur, H., Ko, Y. T., Min, B. S., Kim, K. S., Choi, J. S., Sohn, S. K., Cho, C. H., Ko, H. K., Lee, J. T., and Kim, N. K. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. American Journal of Surgery 197: 728–736, 2009.CrossRefPubMed
19.
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., and Stroup, D. F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354: 1896–1900, 1999.CrossRefPubMed
20.
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. J., and McQuay, H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled clinical trials 17: 1–12, 1996.CrossRefPubMed
21.
Abdalla, E. K., Vauthey, J. N., Ellis, L. M., Ellis, V., Pollock, R., Broglio, K. R., Hess, K., and Curley, S. A. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of Surgery 239: 818–825; discussion 825–817, 2004CrossRefPubMed
22.
Berber, E., Tsinberg, M., Tellioglu, G., Simpfendorfer, C. H., and Siperstein, A. E. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 12: 1967–1972, 2008.CrossRefPubMed
23.
Elias, D., Baton, O., Sideris, L., Matsuhisa, T., Pocard, M., and Lasser, P. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Annals of Surgical Oncology 11: 500–505, 2004.CrossRefPubMed
24.
Oshowo, A., Gillams, A., Harrison, E., Lees, W. R., and Taylor, I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. The British journal of Surgery 90: 1240–1243, 2003.CrossRefPubMed
25.
Reuter, N. P., Woodall, C. E., Scoggins, C. R., McMasters, K. M., and Martin, R. C. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 13: 486–491, 2009.CrossRefPubMed
26.
Aloia, T. A., Vauthey, J. N., Loyer, E. M., Ribero, D., Pawlik, T. M., Wei, S. H., Curley, S. A., Zorzi, D., and Abdalla, E. K. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141: 460–466; discussion 466–467, 2006CrossRefPubMed
27.
Otto, G., Duber, C., Hoppe-Lotichius, M., Konig, J., Heise, M., and Pitton, M. B. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Annals of Surgery, 2009. doi:10.​1097/​SLA.​0b013e3181bc9fae​
28.
Ogihara, M., Wong, L. L., and Machi, J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford) 7: 214–221, 2005
29.
Guglielmi, A., Ruzzenente, A., Valdegamberi, A., Pachera, S., Campagnaro, T., D’Onofrio, M., Martone, E., Nicoli, P., and Iacono, C. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 12: 192–198, 2008.CrossRefPubMed
30.
Chagnon, S. [Prospective randomized trial of radiofrequency ablation versus surgical resection for small hepatocellular carcinomas]. Journal de Radiologie 88: 1842–1844, 2007.CrossRefPubMed
31.
Ueno, S., Sakoda, M., Kubo, F., Hiwatashi, K., Tateno, T., Baba, Y., Hasegawa, S., and Tsubouchi, H. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. Journal of Hepato-Biliary-Pancreatic Surgery 16: 359–366, 2009.CrossRefPubMed
32.
Santambrogio, R., Opocher, E., Zuin, M., Selmi, C., Bertolini, E., Costa, M., Conti, M., and Montorsi, M. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Annals of Surgical Oncology 16: 3289–3298, 2009.CrossRefPubMed
33.
Leblanc, F., Fonck, M., Brunet, R., Becouarn, Y., Mathoulin-Pelissier, S., and Evrard, S. Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol 34: 185–190, 2008.PubMed
34.
Chen, M. S., Li, J. Q., Zheng, Y., Guo, R. P., Liang, H. H., Zhang, Y. Q., Lin, X. J., and Lau, W. Y. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery 243: 321–328, 2006.CrossRefPubMed
35.
Cho, C. M., Tak, W. Y., Kweon, Y. O., Kim, S. K., Choi, Y. H., Hwang, Y. J., and Kim, Y. I. [The comparative results of radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma.]. The Korean Journal of Hepatology 11: 59–71, 2005.PubMed
36.
Hong, S. N., Lee, S. Y., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., Rhee, J. C., Choi, D., Lim, H. K., Lee, K. W., and Joh, J. W. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. Journal of Clinical Gastroenterology 39: 247–252, 2005.CrossRefPubMed
37.
Hasegawa, K., Makuuchi, M., Takayama, T., Kokudo, N., Arii, S., Okazaki, M., Okita, K., Omata, M., Kudo, M., Kojiro, M., Nakanuma, Y., Takayasu, K., Monden, M., Matsuyama, Y., and Ikai, I. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. Journal of Hepatology 49: 589–594, 2008CrossRefPubMed
38.
Vivarelli, M., Guglielmi, A., Ruzzenente, A., Cucchetti, A., Bellusci, R., Cordiano, C., and Cavallari, A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Annals of Surgery 240: 102–107, 2004.CrossRefPubMed
39.
Lee, W. S., Yun, S. H., Chun, H. K., Lee, W. Y., Kim, S. J., Choi, S. H., Heo, J. S., Joh, J. W., Choi, D., Kim, S. H., Rhim, H., and Lim, H. K. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. Journal of Clinical Gastroenterology 42: 945–949, 2008.CrossRefPubMed
40.
White, R. R., Avital, I., Sofocleous, C. T., Brown, K. T., Brody, L. A., Covey, A., Getrajdman, G. I., Jarnagin, W. R., Dematteo, R. P., Fong, Y., Blumgart, L. H., and D’Angelica, M. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 11: 256–263, 2007.CrossRefPubMed
41.
Molinari, M., and Helton, S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. American Journal of Surgery 198: 396–406, 2009.CrossRefPubMed
42.
Lu, M. D., Kuang, M., Liang, L. J., Xie, X. Y., Peng, B. G., Liu, G. J., Li, D. M., Lai, J. M., and Li, S. Q. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 86: 801–805, 2006.PubMed
43.
Adams, R. B., Haller, D. G., and Roh, M. S. Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et al. Annals of Surgical Oncology 13: 1281–1283, 2006.CrossRefPubMed
44.
Birth, M., Hildebrand, P., Dahmen, G., Ziegler, A., Broring, D. C., Hillert, C., and Bruch, H. P. [Present state of radio frequency ablation of liver tumors in Germany]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 75: 417–423, 2004PubMed
45.
Pawlik, T. M., Schulick, R. D., and Choti, M. A. Expanding criteria for resectability of colorectal liver metastases. The Oncologist 13: 51–64, 2008.CrossRefPubMed
46.
Baize, N., Gerard, B., Bleiberg, H., Caroli-Bosc, F., Berthier, F., Legendre, H., Pector, J. C., and Hendlisz, A. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterologie clinique et biologique 30: 1349–1353, 2006.CrossRefPubMed
Metadaten
Titel
Radiofrequency Ablation Versus Resection for Liver Tumours: An Evidence-Based Approach to Retrospective Comparative Studies
verfasst von
Gianpiero Gravante
John Overton
Roberto Sorge
Neil Bhardwaj
Matthew S. Metcalfe
David M. Lloyd
Ashley R. Dennison
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1377-6

Weitere Artikel der Ausgabe 2/2011

Journal of Gastrointestinal Surgery 2/2011 Zur Ausgabe

Original Article

A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations

Original Article

Radiofrequency Ablation Versus Surgical Resection for Hepatocellular Carcinoma in Childs A Cirrhotics—a Retrospective Study of 1,061 Cases

Original Article

The Cholecystokin Provocation HIDA Test: Recreation of Symptoms is Superior to Ejection Fraction in Predicting Medium-Term Outcomes

Original Article

An Analysis of the Utility of Handheld PET Probes for the Intraoperative Localization of Malignant Tissue

Original Article

Management and Outcome of Intrathoracic Bleeding due to Vascular Injury During Transhiatal Esophagectomy

Original Article

Predictive Value of POSSUM and ACPGBI Scoring in Mortality and Morbidity of Colorectal Resection: A Case–Control Study

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise